Aligos Therapeutics (ALGS) Net Margin (2021 - 2026)

Aligos Therapeutics (ALGS) has reported Net Margin for 6 consecutive years, with 814.13% the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Net Margin fell 1466880.0% year-over-year to 814.13%; the trailing twelve-month figure through Jun 2026 stood at 1888.58% (up 48000.0% YoY), and the FY2025 full-year result was 862.95%, up 277070.0% from the prior year.
• Net Margin grew to 814.13% in Q1 2026 per ALGS's latest filing, from 8610.65% in the prior quarter.
• Across five years, Net Margin topped out at 13854.66% in Q1 2025 and bottomed at 13556.11% in Q4 2024.
• Historically, Net Margin has averaged 1627.21% across 5 years, with a median of 888.7% in 2023.
• The sharpest annual moves came in 2025 and 2026: Net Margin jumped 1887815 bps in 2025, then tumbled 1466880 bps in 2026.
• Over 5 years, Net Margin stood at 618.77% in 2022, then tumbled by 124 bps to 1388.35% in 2023, then slumped by 876 bps to 13556.11% in 2024, then soared by 36 bps to 8610.65% in 2025, then jumped by 91 bps to 814.13% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 814.13%, 8610.65%, and 4256.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.